Japanese Drug Makers See M&As For Technology, Not Size
This article was originally published in PharmAsia News
Executive Summary
An about-to-be completed merger of two Japanese drug makers represents a change in the mergers and acquisitions practice. It used to be Japanese pharmaceuticals would acquire foreign firms to become larger, but now they are likely to merge to get new technologies to make them more competitive. Kyowa Hakko Kogyo, a subsidiary of Kinn Holdings, is set to acquire Kirin Pharma on Oct. 1, to become Kyowa Hakko Kinn to take advantage of the ability to combine technology, primary in developing new antibodies. (Click here for more - a subscription may be required